Allogene Therapeutics Wins Arbitration Against Cellectis
Allogene Therapeutics (ALLO) noted the favorable outcome for Servier in its arbitration with Cellectis (CLLS) as it relates to cemacabtagene ansegedleucel. This decisive win reconfirmed Allogene's full development and commercial control of cema-cel in the United States, all EU Member States, and the United Kingdom, while clearing the path to obtain full global commercialization rights from Servier. In particular, the tribunal: Rejected Cellectis's allegations relating to alleged breaches by Servier of its development obligations; Rejected Cellectis's financial claims, finding that milestone payments tied to the pivotal trial are not due until U.S. FDA acceptance of a Biologics License Application; and Ordered only a partial termination of the license strictly limited to the UCART19 V1 product (formerly known as ALLO-501, which was discontinued in 2021 in favor of ALLO-501A/cema-cel) and directed Cellectis to negotiate in good faith a direct license to Allogene on terms substantially similar to the existing agreement, if Allogene elects to pursue it. With this legal matter resolved, Allogene enters 2026 with improved fundamentals. The company is approaching one of the most meaningful catalyst periods in the allogeneic CAR T field, including a 1H 2026 interim futility analysis comparing MRD conversion with cema-cel following standard fludarabine/cyclophosphamide lymphodepletion versus observation in first line patients with large B-cell lymphoma.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on ALLO
About ALLO
About the author
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
- Price Surge: ImmunityBio's stock price has tripled over three weeks, closing at $6.92 on Wednesday with a 6.79% increase, indicating strong market interest in its immunotherapy developments, potentially attracting more investors.
- Volume Spike: Trading volume reached 93.5 million shares on Wednesday, about 357% above the three-month average of 20.5 million shares, signaling a significant rise in investor attention that could lead to further price volatility.
- Short-Seller Losses: With 35% of the public float held short, short-sellers now face nearly $500 million in paper losses, reflecting optimistic market sentiment towards ImmunityBio's future developments, which may prompt short-covering to mitigate losses.
- Market Reaction: Although there was no specific news driving the price increase, the actions of short-sellers covering their positions combined with recent positive developments have contributed to the stock's rise, showcasing ongoing interest in the biotechnology sector.
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in GOBLET Cohort 4, significantly surpassing the historical benchmark of 10%, indicating substantial clinical value in third-line anal cancer patients with no FDA-approved treatment options.
- Duration of Response: The median duration of response reached approximately 17 months, far exceeding the standard treatment's 9.5 months, showcasing pelareorep's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Interaction Plan: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss its registration-directed clinical study plan for second-line and later SCAC, with the potential for accelerated approval if data meets expectations.
- Strategic Investment and Expansion: The company is enhancing its expertise in gastrointestinal oncology through the expansion of its Scientific Advisory Board, further validating its Phase 3 study design for first-line metastatic pancreatic cancer, demonstrating its strategic positioning in the oncology immunotherapy landscape.
